[ad_1]
WILLIAMSVILLE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a number one plant-based, biotechnology firm centered on tobacco hurt discount, very low nicotine content material tobacco, and hemp/hashish analysis, introduced right now that it was granted a brand new U.S. patent associated to the management of cannabinoid and terpene manufacturing in vegetation. This new mental property completely offers 22nd Century with distinctive and highly effective instruments to change the cannabinoid biosynthesis pathway in hemp/hashish vegetation.
“We’re delighted to obtain this patent, which is the results of work carried out by our personal scientists. This essential, new know-how will enable us to genetically modify hemp/hashish vegetation to modulate their cannabinoid and terpene profiles with a view to tailor these vegetation’ therapeutic qualities and improve the patron’s hemp/hashish expertise,” stated Juan Sanchez Tamburrino, Ph.D., vp of analysis & growth at 22nd Century Group. “Our patent software describes eight promoters, that are primarily molecular on/off switches, masking all the main steps within the cannabinoid biosynthesis pathway. Usually, creating hemp/hashish vegetation with new cannabinoid or terpene profiles might take 10 to 20 years utilizing conventional breeding strategies. Now, with the mixed applied sciences and know-how of 22nd Century and KeyGene, we count on to shorten the event timeline to create new, differentiated, hemp/hashish plant traces in simply four to five years. Doing so will present the Firm and its potential licensees and prospects with important aggressive benefit as hemp/hashish continues to penetrate the life science, client product, and pharmaceutical markets.”
“At 22nd Century Group, we take a scientific and solutions-oriented method to advancing ground-breaking, plant-based know-how. We’re excited to safe this patent, and we imagine that it demonstrates our distinctive and main position in plant science innovation throughout the $100 billion world hemp/hashish market,” stated James A. Mish, chief government officer of 22nd Century Group.
The brand new patent, printed as U.S. Patent No. 10,787,674 B2 and entitled “Trichome particular promoters for the manipulation of cannabinoids and different compounds in glandular trichomes,” allows 22nd Century to develop and ship new hemp/hashish vegetation which can be designed to provide cannabinoids extra effectively. The Firm can probably improve the yield of vegetation, stabilize the extent of cannabinoids which can be produced, and create customized cannabinoid profiles optimized for particular therapeutic makes use of. 22nd Century can even be capable to probably modulate the terpene ranges throughout the plant – rising them to ship new strains of hashish for the adult-use/leisure market and lowering them to take away the odor and style for improved software in meals and drinks.
Cannabinoids, corresponding to CBD, CBC, and CBG, are invaluable compounds that maintain nice promise for the event of latest medicines and different therapeutic purposes. Hashish sativa is the one plant species that produces important quantities of those compounds together with a couple of hundred completely different cannabinoids in various portions. In nature, hashish vegetation limit manufacturing of those probably poisonous compounds to the trichomes that are tiny hair-like stems and globes that develop on the floor of the plant. To efficiently manipulate cannabinoids, the Firm’s new know-how prompts molecular promoters, “on/off switches,” particularly and solely within the plant’s trichomes the place the vast majority of cannabinoids are produced. These regulatory sequences dynamically improve or limit gene expression ranges, controlling the expression of genetic data that results in the manufacturing of cannabinoids.
About 22nd Century Group, Inc.
22nd Century Group, Inc. (NYSE American: XXII) is a number one plant biotechnology firm centered on applied sciences that alter the extent of nicotine in tobacco vegetation and the extent of cannabinoids in hemp/hashish vegetation by way of genetic engineering, gene-editing, and trendy plant breeding. 22nd Century’s main mission in tobacco is to scale back the hurt attributable to smoking by way of the Firm’s proprietary diminished nicotine content material tobacco cigarettes – containing 95% much less nicotine than standard cigarettes. The Firm’s main mission in hemp/hashish is to develop and commercialize proprietary hemp/hashish vegetation with invaluable cannabinoid profiles and fascinating agronomic traits.
Study extra at xxiicentury.com, on Twitter @_xxiicentury and on LinkedIn.
Cautionary Word Relating to Ahead-Trying Statements
Apart from historic data, all the statements, expectations, and assumptions contained on this press launch are forward-looking statements. Ahead-looking statements sometimes comprise phrases corresponding to “anticipate,” “imagine,” “take into account,” “proceed,” “might,” “estimate,” “count on,” “discover,” “foresee,” “objective,” “steerage,” “intend,” “probably,” “might,” “plan,” “potential,” “predict,” “preliminary,” “possible,” “mission,” “promising,” “search,” “ought to,” “will,” “would,” and comparable expressions. Precise outcomes might differ materially from these express or implicit in forward-looking statements. Vital elements that might trigger precise outcomes to vary materially are set forth in “Threat Elements” within the Firm’s Annual Report on Kind 10-Ok filed on March 11, 2020 and on Quarterly Stories on Kind 10-Q. All data supplied on this launch is as of the date hereof, and the Firm assumes no obligation to publicly replace or revise any forward-looking statements because of new data, future occasions, or in any other case, besides as required by legislation.
Investor Relations & Media Contact:
Mei Kuo
Director, Communications & Investor Relations
22nd Century Group, Inc.
(716) 300-1221
mkuo@xxiicentury.com
[ad_2]
Source link